Navigation Links
For Osteoporosis and Osteopenia, Clinical Data and Thought Leaders' Opinions Indicate that AMG-785/CDP-7851 and Odanacatib Have Advantages Over Alendronate
Date:4/4/2013

lls just short of being the future clinical gold standard," said Decision Resources Analyst Pam Narang , Ph.D. "Furthermore, although thought leaders expect AMG-785/CDP-7851 to offer superiority over alendronate across all efficacy attributes, the drug's anticipated safety and tolerability profile gives it the edge over current and emerging osteoporosis and osteopenia agents."

According to insights from surveyed U.S. and European PCPs and managed care organization (MCO) pharmacy directors, greater reduction in the risk of vertebral fracture is one of the greatest unmet needs in osteoporosis and osteopenia. Clinical data and the opinions of interviewed thought leaders indicate that Radius Health's BA-058 and AMG-785/CDP-7851 have demonstrated the potential to significantly fulfill this unmet need.

The report also finds that surveyed U.S. MCO pharmacy directors are particularly receptive to new osteoporosis and osteopenia therapies that offer 50 percent better reduction in the risk of vertebral fractures over currently available therapies. Decision Resources expects that BA-058 and AMG-785/CDP-7851 will match the improvements on vertebral fracture risk reduction that surveyed U.S. payers indicated would be required for widespread inclusion on MCO formularies.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Res
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Active Lifes BioDent Reference Point Indenter Validated in Study Published by Osteoporosis Medical Opinion Leaders
2. Unigenes Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
3. Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)
4. Array BioPharma Announces Updates on ARRY-520 Clinical Data at the 2013 International Myeloma Workshop
5. VG Life Sciences Reports Positive Safety Results from Second Cohort Enrollment in Solid Tumor Clinical Trial
6. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
7. NorDx Enhances Clinical Laboratory Diagnostic Services with State-of-the-Art Technology
8. AG Mednet and Japans Biovisiq Bring Zero-Delay Clinical Trial Solutions to Asian Pharmaceutical Market
9. N30 Pharma Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
10. Inovio Collaborator ChronTech Reports Interim Phase II Clinical Study Results from ChronVac-C Vaccine for Hepatitis C Infection
11. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Novation, the leading health care supply ... new IT value-added reseller (VAR) national contracts that ... IT goods and services at lower costs. These ... as value-added services such as initiative assistance and ... Novation agreements were awarded to CDW Government, Paragon ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ... dermatology for clinical and aesthetic dermatology practitioners in the ...
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very ... Mark King as its new Chief Executive Officer.  ... Operating Officer, in which he has overseen the company,s ... Mississippi , and Costa Rica.  Mr. King ... broad-based operations, sales, engineering and manufacturing experience in medical ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... With 30 Installed Inveon Imaging Systems, Siemens ... Position in Preclinical Imaging Centers, HOFFMAN ... adage,says "a picture is worth 1,000 words," ... research where high-resolution images can validate years ...
... Results Seen Since Presentation ... to Include Alvespimycin Plus Trastuzumab Plus ... Paclitaxel Regimen, HAYWARD, ... data from a Phase 1 clinical,trial showing that alvespimycin, its second-generation Hsp90 ...
Cached Medicine Technology:Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 2Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 3Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 4Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 5Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 2Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 3Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 4Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 5
(Date:4/16/2014)... Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that ... CDX-1401 in solid tumors, including long-term patient follow-up, ... (Vol 6 Issue 232). The data demonstrate ... of clinical benefit in patients with very advanced ... to better outcomes on subsequent therapy with checkpoint ...
(Date:4/16/2014)... According to a new study, endoscopists, recommendations for ... to two small polyps are consistent with guideline recommendations ... an appropriate target for quality indicators. This is the ... guidelines for timing of repeat colonoscopy after one to ... average-risk patients. The study appears in the April issue ...
(Date:4/15/2014)... diabetes and pre-diabetes in the United States have nearly ... Hopkins Bloomberg School of Public Health, with obesity apparently ... that the burden of the disease has not hit ... blacks, Hispanics and the elderly. , According to new ... the Annals of Internal Medicine , diabetes increased ...
(Date:4/15/2014)... decades-old medical mystery and in the process have found ... which kill about 1.5 million people a year. The researchers ... an antifungal drug that has been in use for more ... toxic to human cells as it is to the microbes ... findings appears in Nature Chemical Biology . , "Invasive ...
(Date:4/15/2014)... Diego School of Medicine have identified a mechanism that ... liver disease and why the virus is able to ... The hard-to-kill pathogen, which infects an estimated 200 million ... the mitochondria dismantling the cell,s innate ability to ... dynamics. , The study, published in today,s issue of ...
Breaking Medicine News(10 mins):Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Breaking bad mitochondria 2
... CHAPEL HILL, N.C., Nov. 2 With ... the manufacturing environment, best-in-class,companies continue to focus ... internal and external customer relationships. In reviewing,the ... more,than three-quarters of the benchmark class posts ...
... 2 Addressing more than,100 cardiologists and other ... and CEO, set out four critical priorities for,improving ... at,Schering-Plough,s fourth annual Cardiovascular Summit in advance of ... In his speech, Hassan emphasized the potential for ...
... Hair to Help ... Women with Cancer, CINCINNATI, Nov. 2 Two-time Oscar winner,Hilary ... of support for women with cancer. This national campaign,encourages people to ... create free wigs for women who have lost their hair due ...
... Recent outbreaks of,antibiotic-resistant Staphylococcus aureus, more commonly known as ... healthy people,can carry on the skin or nose, it is ... the skin, in the blood, in the bones and,in the ... of antibiotics.,While most of these infections are minor, some however, ...
... Icon Supports Bargaining for Improved Patient Care, HUNTINGTON ... and co-founder of the United Farm Workers of,America, will ... Park for a walkthrough to shed light on patient ... year, caregivers have been seeking a new contract at,the ...
... Technique just as effective in patients under 60, study finds ... known as brachytherapy, are just as effective for treating prostate ... older men, a new study finds. , Brachytherapy is ... placed in the prostate to kill cancer cells. Recovery time ...
Cached Medicine News:Health News:Manufacturing Organizations Identify Efficiencies in Credit and Collections Functions 2Health News:Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment 2Health News:Hilary Swank Donates Her Hair to Pantene(R) Beautiful Lengths(TM) 2Health News:Hilary Swank Donates Her Hair to Pantene(R) Beautiful Lengths(TM) 3Health News:Hilary Swank Donates Her Hair to Pantene(R) Beautiful Lengths(TM) 4Health News:Radiation Seed Treatment Helps Younger Men Fight Prostate Cancer 2
... Freedom leg bags are part ... a versatile line of leg bags, ... the varied needs of our customers. ... several sizes, and constructed of 100% ...
... part of the Freedom Urinary Collection ... bags, kits, and accessories designed to ... customers. These leg bags are offered ... 100% latex-free soft, textured medical grade ...
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
Medicine Products: